Clinical Research Directory

Inclusion Criteria: * 18 years of age or older * Has focal Hepatocellular Carcinoma and is deemed to benefit from Yttrium-90 radioembolization by the institutional multidisciplinary tumor board Exclusion Criteria: * All subjects meeting any of the exclusion criteria at baseline will be excluded from study participation. * The presence of trans-jugular intrahepatic portosystemic shunt * Total bilirubin level \> 3.0 mg/dL * Serum albumin level \< 2.5 g/dL * Aspartate and alanine aminotransferase levels no greater than five times the normal level * Life expectancy \< 12 weeks * Eastern Cooperative Oncology Group performance status \> 2 * Patients with chronic lung disease requiring supplemental oxygen at baseline or baseline SpO2 of \<92% * Patients that have tumors with central anatomical locations close the hepatic hilum or caudate lobe. * Patients with macrovascular invasion on baseline imaging * Known hypersensitivity to iodinated contrast agents or to any component of iodinated contrast agents refractory to standard medications (antihistamines, steroids) * Impaired kidney function (glomerular filtration rate \< 30 as approximated using serum creatinine levels) unless anuric and on dialysis. * Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-HCG results, obtained within 48 hours prior to the treatment or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)